» Articles » PMID: 33267820

Relationship Between Surgical R0 Resectability and Findings of Peripancreatic Vascular Invasion on CT Imaging After Neoadjuvant S-1 and Concurrent Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer

Abstract

Background: Borderline resectable pancreatic cancer (BRPC) is frequently associated with positive surgical margins and a poor prognosis because the tumor is in contact with major vessels. This study evaluated the relationship between the margin-negative (R0) resection rate and findings indicating peripancreatic vascular invasion on multidetector computed tomography (MDCT) imaging after neoadjuvant chemoradiotherapy (NACRT) in patients with BRPC.

Methods: Twenty-nine BRPC patients who underwent laparotomy after neoadjuvant S-1 with concurrent radiotherapy were studied retrospectively. Peripancreatic major vessel invasion was evaluated based on the length of tumor-vessel contact on MDCT. The R0 resection rates were compared between the progression of vascular invasion (PVI) group and the non-progression of vascular invasion (NVI) group.

Results: There were 3 patients with partial responses (10%), 25 with stable disease (86%), and 1 with progressive disease (3%) according to the RECISTv1.1 criteria. Regarding vascular invasion, 9 patients (31%) were classified as having PVI, and 20 patients (69%) were classified as having NVI. Of the 29 patients, 27 (93%) received an R0 resection, and all the PVI patients received an R0 resection (9/9; R0 resection rate = 100%) while 90% (18/20) of the NVI patients underwent an R0 resection. The exact 95% confidence interval of risk difference between those R0 resection rates was - 10.0% [- 31.7-20.4%].

Conclusions: Patients with BRPC after NACRT achieved high R0 resection rates regardless of the vascular invasion status. BRPC patients can undergo R0 resections unless progressive disease is observed after NACRT.

Trial Registration: UMIN-CTR, UMIN000009172 . Registered 23 October 2012.

Citing Articles

The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuvant FOLFIRINOX.

Barenboim A, Mercer D, Sahnan K, Gaffan A, Goren O, Halperin S J Clin Med. 2024; 13(17).

PMID: 39274419 PMC: 11396552. DOI: 10.3390/jcm13175206.


Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress.

Wu H, Li J, Li J, Zhai Q, Ye J, Zheng S World J Gastrointest Surg. 2023; 15(2):142-162.

PMID: 36896309 PMC: 9988647. DOI: 10.4240/wjgs.v15.i2.142.


Borderline resectable pancreatic cancer: Certainties and controversies.

Nappo G, Donisi G, Zerbi A World J Gastrointest Surg. 2021; 13(6):516-528.

PMID: 34194610 PMC: 8223708. DOI: 10.4240/wjgs.v13.i6.516.

References
1.
Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K . A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012; 85(1):163-9. DOI: 10.1016/j.ijrobp.2012.03.059. View

2.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

3.
Bjerregaard J, Mortensen M, Schonnemann K, Pfeiffer P . Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer. 2012; 49(1):98-105. DOI: 10.1016/j.ejca.2012.07.017. View

4.
Evans D, Rich T, Byrd D, Cleary K, Connelly J, Levin B . Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127(11):1335-9. DOI: 10.1001/archsurg.1992.01420110083017. View

5.
Russo S, Ammori J, Eads J, Dorth J . The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol. 2016; 12(5):669-85. PMC: 5549642. DOI: 10.2217/fon.15.335. View